```html

Zollinger‑Ellison Gastritis

What is Zollinger‑Ellison gastritis?

Zollinger‑Ellison gastritis is an inflammatory condition of the stomach lining that results from the excessive secretion of gastric acid driven by a gastrin‑producing tumor (a Zollinger‑Ellison syndrome, or ZES tumor). The tumor, called a gastrinoma, is most often located in the pancreas or the duodenum and releases large amounts of the hormone gastrin. Gastrin normally stimulates parietal cells to produce acid, but in ZES the hormone is over‑produced, leading to persistent, high‑ volume acid that damages the gastric mucosa, causing gastritis and often multiple peptic ulcer diseases.

While the term “Zollinger‑Ellison gastritis” is not commonly used in the peer‑reviewed literature, it reflects the gastric inflammation that accompanies the classic Zollinger‑Ellison syndrome. Patients typically present with symptoms of severe ulcer disease that are refractory to standard therapy, and the underlying gastrinoma may be sporadic or part of multiple endocrine neoplasia type 1 (MEN‑1).

Sources: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American College of Gastroenterology.

Common Causes

The primary cause of Zollinger‑Ellison gastritis is a gastrinoma, but several related conditions can contribute to the same pathophysiologic cascade of hypergastrinemia and acid over‑production.

• Gastrinoma (Zollinger‑Ellison tumor) – a neuroendocrine tumor of the pancreas or duodenum.
• Multiple endocrine neoplasia type 1 (MEN‑1) – hereditary syndrome that includes gastrin‑producing tumors.
• Familial isolated gastrinoma – rare inherited form without other MEN‑1 features.
• Chronic atrophic gastritis with hypergastrinemia – loss of acid‑producing cells leads to compensatory gastrin rise.
• Proton‑pump inhibitor (PPI) rebound hypergastrinemia – long‑term high‑dose PPI therapy can elevate gastrin levels.
• Renal failure – reduced clearance of gastrin increases circulating levels.
• Helicobacter pylori infection – chronic infection can stimulate gastrin release, though usually not to ZES levels.
• Chronic gastritis caused by autoimmune destruction – similar mechanism to atrophic gastritis.
• Other neuroendocrine tumors (e.g., bronchial or gastric carcinoids) – can secrete gastrin ectopically.
• Rare gastrin‑secreting pancreatic islet cell hyperplasia – diffuse hyperplasia rather than a discrete tumor.

Associated Symptoms

Because the excess acid damages the stomach lining and the duodenum, patients often experience a combination of gastrointestinal and systemic symptoms:

• Severe, burning epigastric pain that may improve briefly after eating (ulcer pain) but often recurs.
• Recurrent or refractory peptic ulcers in the duodenum, jejunum, or even the distal stomach.
• Heartburn and acid reflux (GERD) that is unusually resistant to over‑the‑counter medications.
• Frequent nausea, vomiting, or vomiting of blood (hematemesis) if an ulcer erodes a blood vessel.
• Occult or overt gastrointestinal bleeding leading to iron‑deficiency anemia.
• Unexplained weight loss due to chronic pain and malabsorption.
• Diarrhea or steatorrhea (fatty stools) – acid inactivates pancreatic enzymes.
• Symptoms of MEN‑1 when present: hypercalcemia (kidney stones), pituitary abnormalities (headaches, visual changes).

It is important to note that many of these symptoms overlap with more common ulcer disease, which is why specific testing for hypergastrinemia is essential when ulcers are atypical or refractory.

References: Cleveland Clinic, NIH National Cancer Institute, WHO Classification of Tumors.

When to See a Doctor

While occasional heartburn is common, the following warning signs should prompt immediate medical evaluation:

• Persistent epigastric pain that lasts more than 2 weeks or worsens despite OTC antacids.
• Vomiting blood, or material that looks like coffee grounds.
• Black or tarry stools (melena) indicating upper‑GI bleeding.
• Sudden, unexplained weight loss greater than 5 % of body weight in a month.
• Repeated episodes of ulcer disease despite standard treatment.
• Severe diarrhea or foul‑smelling, oily stools.
• Signs of MEN‑1 such as recurrent kidney stones, persistent high calcium, or new hormonal symptoms.

Early assessment is crucial to prevent complications such as perforated ulcers, severe bleeding, or malignant transformation of a gastrinoma.

Diagnosis

Diagnosing Zollinger‑Ellison gastritis involves confirming both the presence of hypergastrinemia and identifying the gastrin‑producing tumor.

Laboratory Tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) is highly suggestive; levels >150 pg/mL with low gastric pH are diagnostic.
• Secretin stimulation test – gastrin rises paradoxically after IV secretin in ZES patients.
• Chromogranin A – a tumor marker often raised in neuroendocrine tumors.
• 24‑hour gastric pH monitoring – demonstrates persistently low pH (<2) despite acid‑suppressive therapy.
• Complete blood count (CBC) – assesses anemia from chronic bleeding.
• Serum calcium, PTH, and vitamin D – screens for MEN‑1 associated hyperparathyroidism.

Imaging Studies

• Contrast‑enhanced CT scan (abdomen & pelvis) – first‑line to locate pancreatic or duodenal gastrinomas.
• Multiphasic MRI – superior for soft‑tissue contrast and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for detecting small neuroendocrine tumors.
• Endoscopic ultrasound (EUS) – allows fine‑needle aspiration of suspected lesions.
• Upper endoscopy (EGD) – visualizes gastritis, ulcerations, and can obtain biopsies to rule out malignancy.

Pathology

If a lesion is biopsied, histology typically shows well‑differentiated neuroendocrine tumor cells positive for gastrin, chromogranin A, and synaptophysin.

Diagnostic Criteria (per WHO & NCCN)

1. Fasting serum gastrin > 1000 pg/mL (or > 150 pg/mL with gastric pH < 2).
2. Positive secretin stimulation test.
3. Radiologic or intra‑operative identification of a gastrinoma.

Meeting any two of the three criteria is usually sufficient for a definitive diagnosis.

Treatment Options

Therapy focuses on two goals: controlling acid hypersecretion and removing or controlling the gastrinoma.

Medical Management

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole, esomeprazole, or pantoprazole 60‑120 mg daily are the cornerstone for acid control.
• H2‑receptor antagonists – used as adjuncts if PPI dose is limited.
• Antacids – provide symptomatic relief but do not treat underlying hypergastrinemia.
• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and may shrink tumor size, especially in metastatic disease.
• Chemotherapy & targeted therapy – for high‑grade or metastatic neuroendocrine tumors (e.g., everolimus, sunitinib).
• Management of MEN‑1 associated hyperparathyroidism – surgical parathyroidectomy or medical control with cinacalcet.

Surgical Options

• Enucleation – removal of solitary gastrinomas (< 2 cm) when clearly localized.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger or multiple duodenal lesions.
• Distal pancreatectomy – for tumors in the body or tail of the pancreas.
• Liver metastasectomy or radiofrequency ablation – considered when disease spreads to the liver.
• Debulking surgery – reduces tumor burden when cure is not feasible, improving symptom control.

Lifestyle & Home Measures

• Take PPIs exactly as prescribed; do not skip doses.
• Avoid alcohol, nicotine, and NSAIDs, which aggravate ulcer formation.
• Eat small, frequent meals and limit spicy or highly acidic foods.
• Stay hydrated; chronic vomiting can lead to electrolyte disturbances.
• Maintain a balanced diet rich in calcium and vitamin D if you have MEN‑1‑related hyperparathyroidism.

Prevention Tips

Because most gastrinomas arise spontaneously, primary prevention is limited. However, several strategies can reduce the risk of complications and aid early detection:

• Familial screening – first‑degree relatives of patients with MEN‑1 should undergo genetic counseling and periodic gastrin level testing.
• Regular medical follow‑up – annual endoscopy and imaging for known gastrinomas, even after resection.
• Limit long‑term high‑dose PPI use unless medically required, to avoid rebound hypergastrinemia.
• Prompt treatment of H. pylori – eradication reduces background gastritis and ulcer risk.
• Control of renal disease – proper management of chronic kidney disease lowers gastrin accumulation.
• Healthy lifestyle – avoid smoking and excess alcohol, both of which promote ulcer disease.

Emergency Warning Signs

Summary

Zollinger‑Ellison gastritis is an aggressive form of gastric inflammation caused by a gastrin‑secreting tumor. The resulting hyperacidic environment leads to refractory ulcers, bleeding, and, in some cases, metastatic disease. Early recognition—especially in patients with multiple or atypical ulcers—allows timely laboratory testing, imaging, and definitive treatment.

Effective management combines high‑dose PPIs for acid suppression, somatostatin analogues to curb gastrin release, and surgical removal of the gastrinoma when feasible. Monitoring for MEN‑1, maintaining regular follow‑up, and adhering to lifestyle recommendations can prevent complications and improve long‑term outcomes.

Always consult a gastroenterologist or an endocrinologist if you suspect Zollinger‑Ellison syndrome; early specialist involvement is essential for optimal care.

References:

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Gastrinoma (Zollinger‑Ellison). https://www.niddk.nih.gov
3. Cleveland Clinic. Zollinger‑Ellison Syndrome – Diagnosis and Treatment. https://my.clevelandclinic.org
4. World Health Organization. WHO Classification of Tumours of the Digestive System, 5th Edition. 2022.
5. American College of Gastroenterology. ACG Clinical Guideline: Management of Gastric Ulcer Disease. 2023.
6. National Comprehensive Cancer Network (NCCN). Neuroendocrine and Adrenal Tumors Guidelines, Version 2.2024.

```